ArticleBMC infectious diseases2026
Respiratory pathogen epidemiology in the post-pandemic era: a multicenter retrospective study from Saudi Arabia.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epidemiology of SARS-CoV-2, Influenza, RSV, and Human Metapneumovirus Across the COVID-19 Era: An Eight-Year Tertiary-Center Study in Saudi Arabia.Pathogens (Basel, Switzerland) · 2026Observational
- Editorial: New discoveries and challenges in pediatric infectious diseases: epidemiological, clinical, and pathogenic advances.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-COVID-19 respiratory pathogen dynamics remain incompletely characterized, particularly in the Arabian Peninsula. Understanding pathogen prevalence, co-infection patterns, and age- and season-specific trends is critical for informing diagnostic strategies, public health monitoring, and prevention strategies.
methodsWe conducted a retrospective, multicenter study across seven tertiary hospitals in three Saudi Arabian regions (Riyadh, Jeddah, Qassim), analyzing 23,074 respiratory samples collected from June 2024 to August 2025 using the QIAstat-Dx Respiratory SARS-CoV-2 Panel (QIAGEN, Hilden, Germany). Demographic, seasonal, and co-infection patterns were assessed and determinants of infection were evaluated. Age-specific and pathogen-specific odds ratios with 95% confidence intervals were calculated using multivariable logistic regression, adjusting for sex, region, and season, with adults aged 18-49 years as the reference group.
resultsAt least one respiratory pathogen was detected in 10,505 samples (45.5%). Single-pathogen infections predominated (88.1%), while co-infections were relatively uncommon (11.9%). Viral pathogens accounted for the majority of detections, with significant age- and region-specific differences identified in multivariable analysis. The most frequently detected pathogens included rhinovirus/enterovirus, influenza A, and RSV, whereas bacterial pathogens were infrequent. Children demonstrated significantly higher odds of adenovirus (adjusted OR 2.8, 95% CI 2.4-3.3), bocavirus (adjusted OR 6.1, 95% CI 4.9-7.6), and RSV (adjusted OR 4.2, 95% CI 3.8-4.7) compared to adults aged 18-49 years, while RSV detection was also elevated in older adults (≥65 years: adjusted OR 2.1, 95% CI 1.8-2.5). Detection rates varied significantly by season, with higher activity in winter and autumn and reduced activity during summer.
conclusionsContemporary respiratory infections in Saudi Arabia are dominated by viral pathogens, with age-specific and seasonal patterns resembling pre-pandemic epidemiology. These findings support targeted monitoring, age-stratified prevention strategies, and evidence-based resource allocation for respiratory disease management in the post-pandemic era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.